Shaokang Wang

Prof. Dr. Shaokang Wang

Southeast University, Nanjing, Jiangsu, China
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
CYChao Yang
Chao Yang
LLLihua Li
Lihua Li
LYLigang Yang
Ligang Yang
HLHui Lǚ
Hui Lǚ
Shaokang WangShaokang Wang
Shaokang Wang
Guiju SunGuiju Sun
Guiju Sun
Until now, little research concerning the lipid-lowering and anti-obesity functions of garlic oil and onion oil has been performed. The objective of this study was to explore the effects of garlic oil and onion oil on serum lipid levels in hyperlipidemia model rats, to provide a scientific basis for the prevention of hyperlipidemia through a dietary approach, and to explore the potential health benefits of garlic and onion. Ninety-six male Sprague-Dawley rats were randomly allocated into eight groups based on their body weight and serum levels of triglycerides (TG) and total cholesterol (TC). The rats received repeated oral administration of volatile oils extracted from garlic and onion for 60 days. Serum lipids and parameters of obesity were examined. The volatile oils suppressed the HFD-induced body weight gain and tended to decrease adipose tissue weight. The oils decreased the levels of TG, TC and LDL-C and increased the serum level of HDL-C compared with the rats in the hyperlipidemia model groups (P < 0.05). The oils were also effective at improving the lipid profile and alleviating hepatic steatosis. Our results implied that garlic oil and onion oil have anti-obesity properties that can counteract the effects of an HFD on body weight, adipose tissue weight, and serum lipid profiles.

31 January 2025 in Frontiers in Global Women's Health
Verified
Journal Article
Open access
PDF file
RWRui Wang
Rui Wang
SXShan Xu
Shan Xu
XHXiaoyu Hao
Xiaoyu Hao
XJXingyi Jin
Xingyi Jin
DPDa Pan
Da Pan
Shaokang WangShaokang Wang
Shaokang Wang
Objectives: Anemia in pregnancy has been a topic of interest for researchers due to its potential impact on various adverse pregnancy outcomes. This study aims to explore the relationship between anemia and adverse pregnancy outcomes such as preterm birth, low birth weight, and maternal mortality.Methods: We conducted both a systematic review and a meta-analysis on the associations between anemia during pregnancy and adverse pregnancy outcomes. We searched Chinese databases (CNKI, Wanfang, CBM, VIP) and English ones (Cochrane Library, PubMed, Embase, Web of Science). Two researcher-authors independently assessed study quality with the Newcastle-Ottawa Scale. After extracting data, we analyzed heterogeneity and used a random-effects model for higher heterogeneity and a fixed-effects model for low heterogeneity in the meta-analysis while also systematically synthesizing and narratively describing findings in the systematic review.Results: A total of 31 cohort studies were included. Meta-analysis showed that the risk of postpartum hemorrhage [RR [95% CI], 2.76 [1.63, 4.66]], premature rupture of membranes (PROM) [1.94 (1.26, 3.00)], preterm delivery [1.51 (1.33, 1.72)], low birth weight (LBW) [1.40 (1.19, 1.63)], cesarean section[1.33 (1.02, 1.74)], gestational hypertension[1.28 (1.14, 1.44)] and neonatal asphyxia[1.21 (1.07, 1.37)] was higher in the group of anemia in pregnancy than in the control group.Conclusion: Maternal anemia is associated with an increased risk of seven adverse pregnancy outcomes: postpartum hemorrhage, PROM, preterm delivery, LBW, cesarean section, gestational hypertension and neonatal asphyxia. Appropriate nutritional supplementation and screening for anemia before and during pregnancy are recommended to improve maternal health and manage adverse pregnancy outcomes.

1 March 2021 in Food Research International
Verified
Journal Article
Closed access
HLHechun Liu
Hechun Liu
HZHangju Zhu
Hangju Zhu
HXHui Xia
Hui Xia
XYXian Yang
Xian Yang
LYLigang Yang
Ligang Yang
Guiju SunGuiju Sun
Guiju Sun

5 July 2022 in Foods
Verified
Journal Article
Open access
PDF file
XCXinyi Cao
Xinyi Cao
JXJiayue Xia
Jiayue Xia
YZYuhao Zhou
Yuhao Zhou
YWYuanyuan Wang
Yuanyuan Wang
HXHui Xia
Hui Xia
Guiju SunGuiju Sun
Guiju Sun
Since the effects of mono-unsaturated fatty acids (MUFA) on lipid profile are still controversial, a meta-analysis of randomized controlled trials was conducted in the present study to assess the effect of MUFA-rich food on lipid profiles. The study was designed, conducted, and reported according to the guidelines of the 2020 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. A systematic and comprehensive search was performed in several databases from inception up to 30 January 2022. The results showed that the intake of edible oil-derived MUFA (EDM) could increase the blood HDL-C level (mean difference = 0.08; 95%CI: −0.01, 0.17, p = 0.03), but did not affect the level of TC, TG, or LDL-C. Moreover, the consumption of other food-derived MUFA (ODM) significantly decreased TG concentration (mean difference = −0.35; 95%CI: −0.61, −0.09, p = 0.01)), but did not affect the level of TC, LDL-C, or HDL-C. Findings from this study suggest that MUFA-rich food might be beneficial to modulate the blood lipid profile.

11 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
XCXinyi Cao
Xinyi Cao
Wang LiaoWang Liao
Wang Liao
HXHui Xia
Hui Xia
Shaokang WangShaokang Wang
Shaokang Wang
Guiju SunGuiju Sun
Guiju Sun
(1) Background: The effects of resveratrol on blood lipids are controversial. Whether there is a dose-response of the lipid profile upon resveratrol supplementation is unknown. (2) Methods: This dose-response meta-analysis of randomized controlled trials (RCTs) was performed to explore the effects of resveratrol supplementation on lipid profile. A systematical and comprehensive search of several databases was conducted by 30 June 2022. (3) Results: The results indicated that the intake of resveratrol could significantly decrease the total cholesterol (TC) (mean difference = −10.28; 95%CI: −13.79, −6.76, p < 0.001), triglyceride (TG) (Mean difference = −856; 95%CI: −12.37, −4.75, p < 0.001) and low-density lipoprotein cholesterol (LDL-C) (mean difference = −5.69; 95%CI: −11.07, −0.31, p = 0.038) level, but did not alter the level of high-density lipoprotein cholesterol (HDL-C). In the non-linear dose–response analysis, we observed a significant effect of the supplementation dosage on the level of LDL-C (p-nonlinearity = 0.002). Results from the sub-group analysis showed that the reduction of LDL-C was more significant in the trials with a duration of ≥12 weeks and in subjects with type 2 diabetes mellitus. (4) Conclusion: Findings from this study suggest that resveratrol may be beneficial to reduce TC, TG, and LDL-C levels in the blood. The dosage of the resveratrol intervention is an essential factor that affects the level of LDL-C.

Verified
Journal Article
Open access
PDF file
ZFZhiyuan Feng
Zhiyuan Feng
XJXia JiaYue
Xia JiaYue
JYJunHui Yu
JunHui Yu
JWJiongnan Wang
Jiongnan Wang
SYShiyu Yin
Shiyu Yin
Guiju SunGuiju Sun
Guiju Sun
Sarcopenia and sarcopenic obesity (SO) represent significant age-related muscular disorders. Their specific biomarkers and pathophysiological mechanisms remain insufficiently elucidated. This study aims to identify differential and shared biomarkers between these conditions to reveal distinct pathophysiological processes, providing a foundation for precision diagnostics and targeted interventions. We conducted a systematic review and meta-analysis of studies examining biomarkers related to sarcopenia and SO in adults aged 45 and older. Electronic and manual searches were performed in PubMed, Web of Science, Cochrane Library, and Embase up to December 2024. The quality of each study was assessed using the National Institutes of Health Quality Assessment Tool. Meta-analysis was performed when at least three studies investigated the same biomarkers in frailty and sarcopenia, calculating the pooled effect size based on the standard mean difference using a random effects model. In total, 80 studies (64 on sarcopenia and 16 on SO) were included, encompassing 36,680 older adults (aged 45 and above) from 16 countries with varying levels of development. Participants were categorized based on their setting, age, and gender distribution. Sarcopenia is characterized by lower serum triglycerides and stable HDL/LDL ratios, while SO presents with higher triglycerides and disrupted cholesterol correlation, indicating distinct metabolic interactions. Analysis of inflammatory profiles revealed significantly elevated CRP levels in SO, with WBC as a specific marker, while TNF-α was associated with sarcopenia, suggesting a subtype-specific role of chronic inflammation. Vitamin D deficiency is prevalent in both conditions and may represent a potential therapeutic target. Subgroup analyses indicated an increased risk of muscle function decline in high-risk communities in developing regions, underscoring the urgent need for early intervention. A set of shared metabolic, hematologic, and inflammatory biomarkers was identified in sarcopenia and SO. These findings address a knowledge gap in biomarker research and highlight the distinct mechanisms involved in the development of both conditions. Developing biomarker-based diagnostic algorithms is essential for optimizing personalized treatment. Subgroup analyses have also identified high-risk populations, underscoring the need for early intervention.